Abstracts tagged "Behcet’s syndrome and treatment"

Abstract Number: 2968 • 2016 ACR/ARHP Annual Meeting
Efficacy of Anti-TNF Alpha in Severe and Refractory Cardiovascular Involvement of Behcet’s Disease: A Multicenter Observational Study of 18 Patients
Anne-Claire Desbois¹, Olga Addimanda², Marc Lambert³, Eric Hachulla³, F. Ackermann⁴, Benjamin subran⁵, Arnaud Hot⁶, Francois Maurier⁷, christelle mausservey⁸, Fanny Bernard⁹, tristan mirault¹⁰, Fleur Cohen¹¹, Laurent Perard¹², Gaelle Leroux¹³, nicolas champtiaux¹⁴, Patrice Cacoub¹⁵ and David Saadoun¹⁶, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²Rheumatology Unit, Istituto Ortopedico Rizzoli, Bologna, Italy, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ⁴internal medicine, Hopital Foch, Suresnes, France, ⁵hopital foch, suresnes, France, ⁶Internal Medicine, Hopital Edouard Herriot, Lyon, France, ⁷Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁸CH Chalon sur saone, Chalon sur saone, France, ⁹CHU Marseille, marseille, France, ¹⁰HEGP, paris, France, ¹¹Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ¹²Hôpital Edouard Herriot, Lyon, France, ¹³Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁴Pitié SAlpétrière, paris, France, ¹⁵Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, ¹⁶Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France
Background/Purpose: In Behçet's disease (BD), vascular complications affect more than 30% patients. Cardiovascular involvement is the main cause of death, especially for pulmonary or aortic…
Abstract Number: 761 • 2013 ACR/ARHP Annual Meeting
Apremilast For The Treatment Of Behçet’s Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind Study
Gulen Hatemi¹, Melike Melikoglu², Recep Tunc³, Cengiz Korkmaz⁴, Banu Turgut Ozturk⁵, Cem Mat⁶, Peter A. Merkel⁷, Kenneth Calamia⁸, Ziqi Liu⁹, Lilia Pineda⁹, Randall M. Stevens⁹, Hasan Yazici² and Yusuf Yazici¹⁰, ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, ⁴Eskisehir Osmangazi University, Eskisehir, Turkey, ⁵Selçuk University, Konya, Turkey, ⁶Istanbul University, Cerrahpasa Medical Faculty, Dermatology, Istanbul, Turkey, ⁷Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ⁸Mayo Clinic, Jacksonville, FL, ⁹Celgene Corporation, Warren, NJ, ¹⁰Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Apremilast for the Treatment of Behçet's Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind StudyBackground/Purpose: Mucocutaneous manifestations of Behçet's syndrome (BS) can be resistant to conventional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].